Eli Lilly and Company (NYSE:LLY) Shares Down 1.4% – Here’s What Happened

Eli Lilly and Company (NYSE:LLY)’s share price traded down 1.4% during trading on Wednesday . The stock traded as low as $1,204.16 and last traded at $1,218.7560. Approximately 2,598,215 shares traded hands during mid-day trading, a decline of 19% from the average daily volume of 3,224,212 shares. The stock had previously closed at $1,235.56.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Royal Bank of Canada raised its price target on Eli Lilly to $1,500 and kept an outperform rating, reinforcing Wall Street’s confidence in continued upside for the obesity and diabetes franchise.
• Positive Sentiment: JPMorgan also lifted its target to $1,400 with an overweight rating, adding to the wave of analyst optimism around Lilly’s growth pipeline and market dominance.
• Positive Sentiment: News that Lilly’s eczema treatment was approved in Canada provides another non-obesity growth driver, signaling the company’s business is broader than just GLP-1 drugs.
• Positive Sentiment: Multiple articles highlighted Lilly’s record-high share price and strong momentum in Mounjaro/Zepbound, while bullish commentary pointed to expanding access and a large long-term obesity market as key growth catalysts.
• Neutral Sentiment: Several “is it too late to buy?” and valuation-focused articles suggest the stock may be expensive after its massive run, which could keep some investors cautious even as fundamentals remain strong.
• Neutral Sentiment: Coverage linking Lilly to broader healthcare ETF strength and biotech sector optimism reflects positive sentiment, but these are more indirect market backdrops than company-specific catalysts.
• Negative Sentiment: One article noted that employers are reducing obesity drug coverage, which could eventually create a headwind for demand and access to Lilly’s weight-loss medicines.

Analysts Set New Price Targets

Several brokerages recently issued reports on LLY. Berenberg Bank upped their price target on Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the stock a “hold” rating in a report on Monday, June 22nd. Wall Street Zen upgraded Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 2nd. Jefferies Financial Group upped their target price on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the stock a “buy” rating in a research note on Tuesday, June 9th. Royal Bank Of Canada increased their target price on shares of Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the company an “outperform” rating in a report on Wednesday. Finally, Truist Financial raised their price target on shares of Eli Lilly and Company from $1,281.00 to $1,370.00 and gave the company a “buy” rating in a research report on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $1,255.89.

Eli Lilly and Company Stock Performance

The stock has a market capitalization of $1.15 trillion, a P/E ratio of 43.30, a price-to-earnings-growth ratio of 1.49 and a beta of 0.51. The company has a 50 day simple moving average of $1,078.08 and a 200-day simple moving average of $1,030.27. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. During the same quarter in the prior year, the company earned $3.34 EPS. The firm’s quarterly revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, equities analysts forecast that Eli Lilly and Company will post 35.74 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a $1.73 dividend. The ex-dividend date is Friday, August 14th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.

Institutional Trading of Eli Lilly and Company

A number of institutional investors have recently modified their holdings of LLY. Spire Wealth Management raised its position in shares of Eli Lilly and Company by 2.2% during the 4th quarter. Spire Wealth Management now owns 27,719 shares of the company’s stock valued at $29,789,000 after buying an additional 592 shares in the last quarter. Coldstream Capital Management Inc. grew its position in Eli Lilly and Company by 25.6% in the third quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company’s stock worth $32,365,000 after acquiring an additional 8,659 shares in the last quarter. Farther Finance Advisors LLC grew its position in Eli Lilly and Company by 30.8% in the fourth quarter. Farther Finance Advisors LLC now owns 31,145 shares of the company’s stock worth $33,471,000 after acquiring an additional 7,338 shares in the last quarter. Iams Wealth Management LLC bought a new position in Eli Lilly and Company in the fourth quarter valued at $754,000. Finally, Militia Capital Partners LP increased its stake in Eli Lilly and Company by 333.3% in the third quarter. Militia Capital Partners LP now owns 2,600 shares of the company’s stock valued at $1,984,000 after acquiring an additional 2,000 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.